全文获取类型
收费全文 | 30299篇 |
免费 | 1839篇 |
国内免费 | 190篇 |
专业分类
耳鼻咽喉 | 205篇 |
儿科学 | 760篇 |
妇产科学 | 437篇 |
基础医学 | 3754篇 |
口腔科学 | 808篇 |
临床医学 | 2063篇 |
内科学 | 7968篇 |
皮肤病学 | 794篇 |
神经病学 | 2438篇 |
特种医学 | 1124篇 |
外科学 | 4920篇 |
综合类 | 141篇 |
一般理论 | 1篇 |
预防医学 | 752篇 |
眼科学 | 437篇 |
药学 | 2102篇 |
中国医学 | 36篇 |
肿瘤学 | 3588篇 |
出版年
2023年 | 218篇 |
2022年 | 160篇 |
2021年 | 832篇 |
2020年 | 425篇 |
2019年 | 574篇 |
2018年 | 785篇 |
2017年 | 618篇 |
2016年 | 693篇 |
2015年 | 744篇 |
2014年 | 919篇 |
2013年 | 1060篇 |
2012年 | 1671篇 |
2011年 | 1772篇 |
2010年 | 979篇 |
2009年 | 800篇 |
2008年 | 1391篇 |
2007年 | 1610篇 |
2006年 | 1462篇 |
2005年 | 1473篇 |
2004年 | 1330篇 |
2003年 | 1188篇 |
2002年 | 1172篇 |
2001年 | 963篇 |
2000年 | 923篇 |
1999年 | 873篇 |
1998年 | 322篇 |
1997年 | 254篇 |
1996年 | 285篇 |
1995年 | 171篇 |
1994年 | 168篇 |
1993年 | 154篇 |
1992年 | 543篇 |
1991年 | 499篇 |
1990年 | 511篇 |
1989年 | 463篇 |
1988年 | 434篇 |
1987年 | 434篇 |
1986年 | 377篇 |
1985年 | 395篇 |
1984年 | 282篇 |
1983年 | 192篇 |
1979年 | 215篇 |
1978年 | 143篇 |
1977年 | 140篇 |
1974年 | 129篇 |
1971年 | 136篇 |
1970年 | 132篇 |
1969年 | 128篇 |
1968年 | 139篇 |
1967年 | 140篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
1.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
2.
Hideyuki Masuda Makoto Kimura Akiko Nishioka Hiroshi Kato Akimichi Morita 《Journal of dermatological science》2019,93(2):109-115
Background
Photosensitizers used for photodynamic therapy (PDT) to treat dermatologic disease are metabolized into mainly protoporphyrin IX (PpIX), which has five absorption wavelength peaks: 410?nm, 510?nm, 545?nm, 580?nm, and 630?nm. Although only red light around 635?nm and blue light around 400?nm are used as light sources for PDT, the efficiency of PDT might be improved by using multiple wavelengths, including those that correspond to the other absorption peaks of PpIX. Furthermore, because the target disease often occurs on the face, a flexible-type light-source unit that can be fitted to the lesion without unnecessarily exposing the mucous membranes, e.g., the eyes, nostrils, and mouth, is preferred.Objective
We investigated the efficacy of a flexible light-emitting diode (LED) unit that emits multiple wavelengths to improve PDT effects.Methods
HaCaT cells were incubated with 5-ALA and subsequently irradiated with either a single wavelength or sequentially with two wavelengths. Cell viability and reactive oxygen species were analyzed. Nude mice were implanted with COLO679 cells by subcutaneous injection into the flank. 5-ALA was subcutaneously injected into the tumor. The tumor was irradiated with 50?J/cm2 (day 0) and assessed daily until day 21.Results
The synergistic PDT effects of dual-wavelength irradiation and reactive oxygen species production were highest with the 405-nm and 505-nm wavelength combination. This dual wavelength combination was also the most effective in vivo.Conclusion
We could therefore conclude that dual-wavelength PDT is an efficient strategy for improving the therapeutic effects of PDT. Using a flexible LED unit is expected to achieve more uniform irradiation of uneven areas. 相似文献3.
4.
5.
Daisuke Ishibashi Takeshi Ishikawa Satoshi Mizuta Hiroya Tange Takehiro Nakagaki Tsuyoshi Hamada Noriyuki Nishida 《Neurotherapeutics》2020,17(4):1836
The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrPC) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the “hot spot,” stabilizes the structure of PrPC and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrP in vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrPSc levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrPSc accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate that in silico drug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00903-9) contains supplementary material, which is available to authorized users. 相似文献
6.
7.
Kohmoto Tomohiro Masuda Kiyoshi Shoda Katsutoshi Takahashi Rizu Ujiro Sae Tange Shoichiro Ichikawa Daisuke Otsuji Eigo Imoto Issei 《Gastric cancer》2020,23(3):403-417
Gastric Cancer - We aimed to identify novel tumor-promoting drivers highly expressed in gastric cancer (GC) that contribute to worsened prognosis in affected patients. Genes whose expression was... 相似文献
8.
9.
Kosuke Yoshihara Takayuki Enomoto Daisuke Aoki Yoh Watanabe Junzo Kigawa Nobuhiro Takeshima Hyoe Inomata Kana Hattori Masahisa Jinushi Hitoshi Tsuda Toru Sugiyama 《Cancer science》2020,111(9):3350-3358
Whether germline (g) breast cancer susceptibility gene (BRCA) mutations are located within or outside the ovarian cancer cluster region (OCCR) (1380‐4062 bp for gBRCA1, and between 3249‐5681 bp and 6645‐7471 bp for gBRCA2) may influence risk variations for ovarian cancers. This ad hoc analysis of the CHARLOTTE epidemiological study in Japan assessed the distribution of gBRCA1/2 mutations in patients with newly diagnosed ovarian cancer, and investigated an association between gBRCA1/2 mutation locations and ovarian cancer risk. Differences in patient background and clinical characteristics in subgroups stratified by gBRCA1/2 mutation locations were also evaluated. We analyzed the data of 93 patients (14.7%) from the CHARLOTTE study who were positive for gBRCA1/2 mutations. After excluding 16 cases with L63X founder mutation, 28 (65.1%) of gBRCA1 mutations were within the OCCR. Of 30 gBRCA2 mutations, 15 (50.0%) were within the OCCR. Of 27 patients (one patient excluded for unknown family history) with gBRCA1 mutations located in the OCCR, 11 (40.7%) had a family history of ovarian cancer; the proportion of patients with a family history of ovarian cancer and gBRCA1 mutations outside the OCCR was lower (13.3%). Sixty percent of patients with gBRCA1 mutations outside the OCCR had a family history of breast cancer; the proportion of patients with a family history of breast cancer and gBRCA1 mutations within the OCCR was relatively lower (33.3%). Understanding the mutation locations may contribute to more accurate risk assessments of susceptible individuals and early detection of ovarian cancer among gBRCA mutation carriers. 相似文献
10.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146